These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33129272)

  • 21. Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease.
    Blank V; Petroff D; Boehlig A; Heinze A; Karlas T; Berg T; Wiegand J
    Eur J Gastroenterol Hepatol; 2022 Jun; 34(6):686-692. PubMed ID: 35102112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Role of Neutrophil-Percentage-to-Albumin Ratio (NPAR) in Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Nondiabetic US Adults: Evidence from NHANES 2017-2018.
    Liu CF; Chien LW
    Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National Health and Nutrition Examination Survey 2017-2018.
    Condon S; Hu H; Kong M; Cave MC; McClain CJ
    Am J Med Sci; 2024 May; 367(5):310-322. PubMed ID: 38307172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD.
    Al-Karaghouli M; Fuentes S; Davyduke T; Ma M; Abraldes JG
    BMJ Open Gastroenterol; 2022 Jan; 9(1):. PubMed ID: 34992072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management.
    Armstrong MJ; Hazlehurst JM; Parker R; Koushiappi E; Mann J; Khan S; Philips A; Chandler L; Johnson J; Round M; Haydon G; Karamat MA; Newsome PN; Tomlinson JW
    QJM; 2014 Jan; 107(1):33-41. PubMed ID: 24131545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Imajo K; Honda Y; Kobayashi T; Nagai K; Ozaki A; Iwaki M; Kessoku T; Ogawa Y; Takahashi H; Saigusa Y; Yoneda M; Kirikoshi H; Utsunomiya D; Aishima S; Saito S; Nakajima A
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):908-917.e11. PubMed ID: 33340780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When the liver gets stiff, the tough get moving.
    Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
    J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.
    Ma N; Bansal M; Chu J; Branch AD
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):229-237. PubMed ID: 38693784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
    Long MT; Noureddin M; Lim JK
    Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Sangha K; Chang ST; Cheung R; Deshpande VS
    Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Barriers and enabling factors in weight management of patients with nonalcoholic fatty liver disease: A qualitative study using the COM-B model of behaviour.
    Gu Y; Zhou R; Kong T; Zhang W; Chen Y; Wang C; Shi J; Hu Y
    Health Expect; 2023 Feb; 26(1):355-365. PubMed ID: 36385729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of a randomized mobile-technology lifestyle program in individuals with nonalcoholic fatty liver disease.
    Tincopa MA; Patel N; Shahab A; Asefa H; Lok AS
    Sci Rep; 2024 Mar; 14(1):7452. PubMed ID: 38548875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
    Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
    Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
    World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening and Referral Practices for Nonalcoholic Fatty Liver Disease by Race and Ethnicity in a Primary Care Clinic.
    Patil R; Nagaraj PK; Kuo HC; Noel G
    J Racial Ethn Health Disparities; 2023 Jun; 10(3):1392-1397. PubMed ID: 35556223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Cassinotto C; Boursier J; Paisant A; Guiu B; Irles-Depe M; Canivet C; Aube C; de Ledinghen V
    Hepatology; 2021 Jun; 73(6):2196-2205. PubMed ID: 33236409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
    J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.